Latest Period
Q2 2026
Security Snapshot
OnKure Therapeutics, Inc. - Class A Common Stock, par value $0.0001 per share (OKUR) Institutional Ownership
CUSIP: 68277Q105
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
75
Shares (Excl. Options)
34,865,728
Price
$4.56
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A Common Stock, par value $0.0001 per share
- Symbol
- OKUR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 34,865,728
- Total 13F value
- $158,986,605
- Portfolio coverage rank
- 0%
- Share change
- +7,325,150
- Value change
- +$34,178,503
- Number of holders
- 75
- Shares outstanding
- 40,703,345
- SEC-reported price per share
- $4.56
- Insider filing price
- $4.56
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- OKUR - OnKure Therapeutics, Inc. - Class A Common Stock, par value $0.0001 per share is tracked under CUSIP 68277Q105.
- 75 institutions reported positions in Q2 2026.
- 15 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 51 to 75 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $113,936,454 to $158,986,605.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 75 institutions filings for Q2 2026.
Security key
68277Q105
Latest holder period
Q2 2026
13F holders
75
13D/G owners
15
CIK / CUSIP context first
Open Q2 2026 holders
OKUR full holder history
OnKure Therapeutics, Inc. SEC filings
OnKure Therapeutics, Inc. company facts
OnKure Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68277Q105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
15
Security
OKUR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| AI Biotechnology LLC | 20% | $24,001,644 | 9,091,532 | AI Biotechnology LLC | 31 Mar 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $10,662,208 | 4,038,715 | RA Capital Management, L.P. | 31 Mar 2026 | |||
| BIOTECHNOLOGY VALUE FUND L P | 8% | +54% | $14,755,148 | +$5,019,967 | 3,235,778 | +52% | BVF PARTNERS L P/IL | 30 Jun 2026 |
| ACORN BIOVENTURES, L.P. | 22% | $7,099,185 | 2,839,674 | Anders Hove | 15 May 2025 | |||
| StepStone Group LP | 6.6% | $7,024,016 | 2,660,612 | StepStone Group LP | 31 Mar 2026 | |||
| Trails Edge Capital Partners, LP | 6% | $6,361,444 | 2,409,638 | Trails Edge Capital Partners, LP | 31 Mar 2026 | |||
| ADAR1 Capital Management, LLC | 5.5% | -8.3% | $10,208,399 | -$894,932 | 2,238,684 | -8.1% | ADAR1 Capital Management, LLC | 30 Jun 2026 |
| Prosight Management, LP | 2.4% | -57% | $4,464,204 | +$1,064,044 | 978,992 | +31% | Prosight Management, LP | 30 Jun 2026 |
| Shay Capital LLC | 6.3% | $2,057,944 | 810,214 | Shay Capital LLC | 15 May 2025 | |||
| CANTOR FITZGERALD & CO. | 5.2% | $1,606,894 | 669,539 | Cantor Fitzgerald Securities | 30 Jun 2025 | |||
| VANGUARD GROUP INC | 4.9% | -12% | $1,815,303 | -$232,174 | 626,593 | -11% | The Vanguard Group | 31 Dec 2025 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 4.2% | -20% | $1,703,014 | -$380,712 | 542,361 | -18% | Highbridge Capital Management, LLC | 31 Dec 2025 |
| Deep Track Capital, LP | 4.1% | $1,330,932 | 523,989 | Deep Track Capital, LP | 31 Dec 2024 | |||
| CITADEL ADVISORS LLC | 1.7% | $700,612 | 223,125 | Kenneth Griffin | 31 Dec 2025 | |||
| Lundbeckfond Invest A/S | 1.6% | $515,930 | 203,122 | Lundbeckfond Invest A/S | 31 Dec 2024 |
As of 30 Jun 2026, 75 institutional investors reported holding 34,865,728 shares of OnKure Therapeutics, Inc. - Class A Common Stock, par value $0.0001 per share (OKUR). This represents 86% of the company’s total 40,703,345 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
79%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.8% | 3,998,333 | 0% | 0.16% | $18,232,398 |
| BVF INC/IL | 7.9% | 3,235,778 | +64% | 0.38% | $14,755,148 |
| ACORN CAPITAL ADVISORS, LLC | 7% | 2,839,674 | 0% | 3.5% | $12,948,913 |
| StepStone Group LP | 6.5% | 2,660,612 | 0% | 0.56% | $12,132,391 |
| ADAR1 Capital Management, LLC | 5.5% | 2,238,684 | -8.1% | 0.48% | $10,208,399 |
| Vivo Capital, LLC | 4.7% | 1,927,710 | 0% | 0.8% | $8,790,358 |
| Vestal Point Capital, LP | 4.5% | 1,825,699 | -0.77% | 0.19% | $8,325,187 |
| BlackRock, Inc. | 3.7% | 1,499,845 | +2925% | 0% | $6,839,294 |
| Trails Edge Capital Partners, LP | 3.5% | 1,438,456 | 1% | $6,559,359 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 1,437,039 | +147% | 0% | $6,552,898 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3% | 1,204,819 | 0% | 0.01% | $5,493,975 |
| CITADEL ADVISORS LLC | 2.9% | 1,187,047 | +3058% | 0% | $5,412,934 |
| Sio Capital Management, LLC | 2.7% | 1,078,965 | 0% | 0.84% | $4,920,080 |
| Prosight Management, LP | 2.4% | 978,992 | -55% | 0.77% | $4,464,204 |
| Logos Global Management LP | 2.4% | 963,855 | 0.19% | $4,395,179 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 724,438 | +634% | 0% | $3,303,461 |
| NEA Management Company, LLC | 1.2% | 478,548 | 0% | 0.14% | $2,182,179 |
| STATE STREET CORP | 1.1% | 463,662 | +3344% | 0% | $2,114,299 |
| Ensign Peak Advisors, Inc | 1.1% | 431,631 | 0% | $1,968,237 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.88% | 358,738 | -4.9% | 0% | $1,635,845 |
| Sofinnova Investments, Inc. | 0.79% | 321,692 | +127% | 0.08% | $1,466,916 |
| Carlyle Group Inc. | 0.66% | 269,895 | 0% | 0.01% | $1,230,721 |
| Seven Fleet Capital Management LP | 0.59% | 240,963 | 0.18% | $1,098,791 | |
| Affinity Asset Advisors, LLC | 0.59% | 240,963 | 0% | 0.05% | $1,098,791 |
| DV EQUITIES, LLC | 0.59% | 240,963 | 0.16% | $1,098,791 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 34,865,728 | $158,986,605 | +$34,178,503 | $4.56 | 75 |
| 2026 Q1 | 27,520,970 | $113,936,454 | +$69,792,277 | $4.14 | 51 |
| 2025 Q4 | 11,055,439 | $31,975,754 | +$1,869,476 | $2.90 | 42 |
| 2025 Q3 | 10,219,418 | $28,103,553 | -$1,295,979 | $2.75 | 41 |
| 2025 Q2 | 10,778,865 | $25,758,405 | -$10,457,913 | $2.39 | 48 |
| 2025 Q1 | 11,945,383 | $50,147,392 | -$1,567,896 | $4.30 | 46 |
| 2024 Q4 | 11,839,453 | $99,220,652 | +$88,963,332 | $8.60 | 50 |
| 2024 Q3 | 3,200 | $5,440 | +$5,440 | $1.70 | 1 |